关于募投项目结项并注销募集资金专项账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 哈尔滨敷尔佳科技股份有限公司（以下简称"公司"）首次公开发行股票募集 资金（包含利息收入和现金管理收益并扣除手续费后的净额）已全部使用完毕，募 集资金投资项目（以下简称"募投项目"）已全部达到预定可使用状态，公司决定 将募投项目全部结项，并注销剩余募集资金专项账户，具体情况公告如下： 一、募集资金基本情况 证券代码：301371 证券简称：敷尔佳 公告编号：2025-021 哈尔滨敷尔佳科技股份有限公司 三、本次结项募投项目的募集资金使用情况 经中国证券监督管理委员会证监许可[2023]1157 号文核准，并经深圳证券交易 所同意，公司由主承销商中信证券股份有限公司于 2023 年 7 月 20 日向社会公众公 开发行普通股（A 股）股票 4,008.00 万股，每股面值 1 元，每股发行价人民币 55.68 元。截至 2023 年 7 月 26 日，公司共募集资金 2,231,654,400.00 元，扣除发行费用 159,889,838.58 元，募集资金净额 2 ...

Group 1 - The cosmetics sector is experiencing a rise, with companies such as Lafang Home (603630) and Huaye Fragrance (300886) hitting the daily limit up [1] - Other companies in the sector, including Jiaheng Home (300955), Shuiyang Co. (300740), Kesi Co. (300856), Qingsong Co. (300132), and Fulejia (301371), are also seeing significant increases in their stock prices [1] - There is a notable influx of dark pool capital into these stocks, indicating strong investor interest [1]

Group 1 - The recombinant protein concept sector declined by 0.82%, ranking among the top declines in concept sectors, with notable declines in companies such as Kexing Pharmaceutical, Jieya Co., and Yipinhong [1] - Among the 14 stocks that rose, Furuida, Borui Pharmaceutical, and Saiseng Pharmaceutical had the highest increases of 10.06%, 3.54%, and 2.90% respectively [1] - The sector experienced a net outflow of 232 million yuan from main funds, with 35 stocks seeing net outflows, and five stocks experiencing outflows exceeding 30 million yuan [2] Group 2 - The top net outflow stock was Saiseng Pharmaceutical, with a net outflow of 65.48 million yuan, followed by Xilong Science, Zhongyuan Qihe, and Borui Pharmaceutical with net outflows of 61.32 million yuan, 53.12 million yuan, and 51.87 million yuan respectively [2][3] - The stocks with the highest net inflows included Furuida, Maiwei Bio, and Ruizhi Pharmaceutical, with net inflows of 189 million yuan, 39.29 million yuan, and 18.25 million yuan respectively [2] - The trading volume and price changes of various stocks in the recombinant protein sector indicate significant market activity, with Saiseng Pharmaceutical showing a trading rate of 35.58% despite the outflow [3]

中国经济网北京6月11日讯敷尔佳（301371）(301371.SZ)今日股价下跌，截至收盘，该股报26.54元，跌 幅1.70%。 敷尔佳于2023年8月1日在深交所创业板上市，发行股份数量为4,008.00万股，发行价格为55.68元/股， 保荐机构(主承销商)为中信证券股份有限公司，保荐代表人为鄢凯红、范新亮。 上市首日，敷尔佳盘中创下最高点80.04元，为该股上市以来最高价。该股目前处于破发状态。 敷尔佳首次公开发行股票的发行费用(不含增值税)合计15,988.98万元，其中保荐及承销费10,745.21万 元。 根据敷尔佳于2025年5月20日披露的2024年年度权益分派实施公告，2024年年度权益分派方案为以总股 本400,080,000股为基数，向全体在册股东按每10股派发现金股利10元人民币(含税)，合计派发现金股利 400,080,000.00元(含税)，以资本公积向全体股东每10股转增3股，共计转增120,024,000股，转增后公司 总股本为520,104,000股，剩余未分配利润结转以后年度分配，本年度不送红股。 敷尔佳首次公开发行股票募集资金总额223,165.44万元，募集资金净额 ...

Group 1 - The A-share port and shipping sector showed strong performance in the afternoon, with significant gains across various companies [1] - China National Aviation Corporation's ocean shipping arm surged over 27%, indicating robust market interest [1] - Companies such as Ningbo Shipping, Ningbo Ocean, Nanjing Port, and Lianyungang all reached their daily limit up, reflecting a bullish sentiment in the sector [1] Group 2 - Jinjiang Shipping and Phoenix Shipping both increased by over 6.5%, contributing to the overall positive trend in the industry [1] - Chongqing Port and Xiamen Port also experienced gains exceeding 5.5%, further highlighting the strength of the port and shipping sector [1]

Group 1 - The core viewpoint of the article highlights the continuous rise of beauty and personal care concept stocks, with Shuiyang Co. and Jieya Co. both increasing by over 10% [1] - The report from Kaiyuan Securities indicates a dual development trend in the cosmetics industry, characterized by a mild recovery and the rise of domestic brands [1] - The concept of "emotional consumption" is identified as a key growth engine in the beauty sector, driven by the ongoing trend of "aesthetic economy" and the deepening of self-consumption ideology [1] Group 2 - Other companies in the sector, such as Huaye Fragrance, Qingsong Co., Kelao Co., and Haoyue Nursing, have also seen stock increases of over 5% [1] - The overall market sentiment is positive, with multiple companies experiencing significant stock price increases, indicating investor confidence in the beauty and personal care market [1]

Core Viewpoint - The company Fulejia (301371) has announced that its Class III medical device, "Recombinant Type III Humanized Collagen Dressing," has passed ethical review for clinical trials and has been registered with the Heilongjiang Provincial Drug Administration, entering the clinical trial phase [1] Group 1: Product Development - The product is intended for auxiliary treatment of wound repair after laser and photon procedures, as well as for repairing skin barrier function damage in sensitive skin patients [1] - The product has completed the necessary ethical review and registration, indicating progress in its development [1] Group 2: Market Potential - There are relatively few similar medical devices and manufacturers in the aesthetic medicine field, suggesting a growing market with significant potential [1] - The domestic production and sales of similar products are increasing rapidly, reflecting a sustained growth in market demand [1]

证券代码：301371 证券简称：敷尔佳 公告编号：2025-020 哈尔滨敷尔佳科技股份有限公司 关于第三类医疗器械产品完成临床试验备案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 近日，哈尔滨敷尔佳科技股份有限公司（以下简称"公司"）在研产品"重 组Ⅲ型人源化胶原蛋白贴敷料"通过该产品临床试验所有中心伦理委员会的伦理 审查，并在黑龙江省药品监督管理局完成分中心盘锦辽油宝石花医院的医疗器械 临床试验备案，公司在研产品"重组Ⅲ型人源化胶原蛋白贴敷料"已经可以开展 临床试验。具体情况公告如下： 一、基本情况 （一）临床试验备案项目一 1、申办者：哈尔滨敷尔佳科技股份有限公司 2、申办地址：哈尔滨市松北区美谷路 500 号 3、试验名称：评价重组Ⅲ型人源化胶原蛋白贴敷料用于激光、光子术后创 面修复辅助治疗的有效性和安全性 4、试验目的：通过与广州创尔生物技术股份有限公司生产的胶原贴敷料对 比，评价公司研制的重组Ⅲ型人源化胶原蛋白贴敷料（MRC-W-T）用于激光、光 子术后面部皮肤创面修复辅助治疗的有效性、安全性 5、试验用医疗器械名称：重组Ⅲ型人源化胶原 ...

Core Viewpoint - The cosmetics retail sales in China for January to April 2025 showed a year-on-year increase of 4%, underperforming the overall retail market by 0.7 percentage points, but this represents an improvement compared to 2024. The industry is characterized by four key trends: innovation in personal care products, breakthroughs in ingredient technology, rising emotional consumption, and the continuation of affordable consumption [1][3]. Investment Recommendations - The company recommends increasing holdings in the personal care sector, highlighting quality companies that benefit from product innovation and opportunities in Douyin channels, with key recommendations including Ruoyuchen (003010), Dengkang Oral (001328), and Runben Co. [2] - In the beauty sector, structural opportunities are identified, with key recommendations for companies like Jinbo Biological, Juzi Biological, and Marubi Co. that are positioned to benefit from the collagen restructuring trend. Additionally, brands like Maogeping, Shumei Co., Proya (603605), and Shanghai Jahwa (600315) are expected to gain from the overall increase in domestic market share [2]. - Companies expected to bottom out and potentially see a turning point include Lafang Household (603630), Shuiyang Co. (300740), Betaini (300957), Furuida (600223), Huaxi Biological, Fulejia (301371), Meilitiantian Medical Health, and Qingsong Co. (300132) [2]. Industry Overview - Demand remains stable, with the rise of domestic brands in the beauty and personal care sectors accelerating. The cosmetics retail sales for January to April 2025 increased by 4% year-on-year, which is a 0.7 percentage point underperformance compared to the overall retail market, but shows improvement from 2024. The overall demand is stable, with leading domestic brands performing well and the rise of new domestic brands spreading from beauty to personal care categories [3][4]. Trends - The industry is witnessing several trends: 1) Personal care transformation with new products in traditional categories, supported by content e-commerce creating a favorable environment for new product launches [4]. 2) Ingredient innovation, particularly in collagen restructuring, with various types and structural innovations expanding application scenarios [4]. 3) Emotional consumption, where cultural, stylistic, and experiential demands are driving the growth of domestic trends in cosmetics and fragrances [4]. 4) Affordable consumption, where the trend for cost-effectiveness continues under supply-demand resonance, benefiting strong supply chains and well-operated brands [4]. Key Companies - Looking ahead to 2025, the market risk appetite is expected to recover significantly. The beauty sector is characterized by substantial changes and a clear trend of rising domestic brands, indicating strong growth potential and leadership in new consumption [5]. The differentiation among brands is increasing, emphasizing the selection of high-growth targets driven by product innovation and attention to marginal improvements [5].

Group 1 - The cosmetics sector is experiencing a rise, with Betaini (300957) increasing by over 10% [1] - Other companies such as Babi Co., Water Sheep Co. (300740), Fulejia (301371), Lafang Jiahua (603630), and Furida (600223) are also seeing gains [1]